The short answer
The IGF-1 receptor was an attractive oncology target because IGF-1 signalling promotes proliferation and opposes cell death. Chen reviewed the programmes in 2013 under the title trials and tribulations, and Yee reviewed anti-IGF therapy in breast cancer in 2018.
Key facts
- Target
- IGF-1 receptor (IGF-1R)
- Rationale
- Proliferative and anti-apoptotic signalling
- Chen 2013
- Chin J Cancer (PMID 23601239)
- Yee 2018
- J Mol Endocrinol (PMID 29378771)
- Outcome
- Programmes largely unsuccessful
- Complication
- Insulin receptor similarity
Why the target looked so promising
IGF-1 receptor signalling drives proliferation and suppresses apoptosis, and elevated signalling had been associated with several cancers. Laron syndrome supplied the human genetic argument. Blocking the receptor should therefore remove a growth signal tumours were using. That is about as clean a rationale as oncology target selection produces.
What happened instead
Chen titled the 2013 review trials and tribulations, which conveys the outcome. Multiple agents entered clinical development and the programmes largely did not deliver the benefit the biology predicted. Yee's 2018 review of anti-IGF therapy in breast cancer covers the same territory in one disease.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
The insulin receptor problem
The IGF-1 receptor and the insulin receptor are structurally close and can form hybrid receptors containing subunits of both. That creates two difficulties: achieving selectivity is hard, and blocking IGF-1R can disturb glucose handling. A target that cannot be engaged without touching insulin signalling has a narrow therapeutic window before anything else is considered.
Redundancy as the deeper problem
Tumours generally depend on more than one growth pathway. Removing one signal frequently produces compensation through another, which is why single-pathway inhibition so often disappoints in oncology. IGF-1R blockade appears to be a clear instance of that pattern rather than an exception to it.
Why the failure does not refute the biology
Laron syndrome concerns lifelong congenital absence of a signal. An antibody given to an adult with established disease is a different intervention entirely, with different timing, different completeness and a different starting point. A pathway can matter for whether cancer arises over decades while blocking it late changes little. Prevention and treatment are different problems.
What this contributes to reading any mechanism claim
That a strong biological rationale, supported by human genetics, is not sufficient. The distance between a mechanism being real and an intervention working is where most drug development fails, and this is one of the better-documented examples of that distance.
Frequently asked questions
Why was IGF-1R an oncology target?
Its signalling promotes proliferation and opposes apoptosis, and Laron syndrome supplied a human genetic argument that the axis matters in cancer.
What happened to those programmes?
They largely failed. Chen's 2013 review is titled 'trials and tribulations', which conveys the outcome accurately.
Does the failure disprove the biology?
No. Lifelong congenital absence and late blockade in established disease are different interventions. Prevention and treatment are different problems.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedChen HX, Sharon E, IGF-1R as an anti-cancer target: trials and tribulations. Chin J Cancer 2013 (PMID 23601239)pubmed.ncbi.nlm.nih.gov
- PubMedYee D, Anti-insulin-like growth factor therapy in breast cancer. J Mol Endocrinol 2018 (PMID 29378771)pubmed.ncbi.nlm.nih.gov
- PubMedLaron Z, Werner H. Endocr Relat Cancer 2023 (PMID 37343154)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- A Regulatory System, Deliberately EvadedIGF binding proteins restrain IGF-1 availability. LR3 exists to escape them. Set against the Laron findings, that is worth stating plainly.
- Two Hormones, One Feedback LoopGrowth hormone acts on the liver, the liver produces IGF-1, and IGF-1 feeds back to suppress growth hormone. Laron syndrome breaks the loop mid-way.
- Two Receptors Close Enough to Form HybridsThe IGF-1 and insulin receptors share structure and can assemble into hybrids containing subunits of both. Selectivity is therefore never absolute.
- Eighty-Three Residues, and What That ChangesRegulators treat 40 amino acids as the boundary between peptide and protein. At 83 residues, IGF-1 LR3 is well past it - with consequences.
- What Is IGF-1 LR3? Why It Is a Protein, Not a PeptideAn 83-residue engineered IGF-1 analogue built to evade binding proteins. Why it is a protein rather than a peptide, and what that changes.